Diligence memo · auto-generated · as of July 2, 2026
XORI Corp
XORI Corp looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
XORI Corp operates in Biotechnology, based in SEATTLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
XORI Corp has raised $2.1M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.1M on 2009-05-01.
Most recent recorded round closed around 2009-05-01.
Valuation (modeled)modeled
Provath models XORI Corp at approximately $93M (range $1.5M–$732M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.90× the median modeled value of Seed Biotechnology companies in 2007–2009 (47 peers) — value vs value, same stage and era. Within the normal band (90% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 17.2 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 29% of Biotechnology peers (4293 compared).
Modeled value ranks above 57% of those peers.
Closest niche peers: Bioassets Development Corp, Aubrey Inc, EndoMetabolic Solutions, Inc., Targegen Inc, Promethean Surgical Devices, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.